Tower Research Capital (TRC)’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $41.1K | Buy |
+712
| New | +$38.9K | ﹤0.01% | 3337 |
|
|
2026
Q2 | – | Sell |
-1,964
| Closed | -$80K | – | 5230 |
|
|
2026
Q1 | $80K | Buy |
1,964
+88
| +5% | +$3.65K | ﹤0.01% | 2362 |
|
|
2025
Q4 | $74.8K | Buy |
1,876
+760
| +68% | +$28.1K | ﹤0.01% | 2147 |
|
|
2025
Q3 | $33.2K | Sell |
1,116
-4,084
| -79% | -$110K | ﹤0.01% | 2855 |
|
|
2025
Q2 | $119K | Sell |
5,200
-3,672
| -41% | -$80.8K | ﹤0.01% | 2239 |
|
|
2025
Q1 | $214K | Sell |
8,872
-1,780
| -17% | -$47.7K | 0.01% | 1327 |
|
|
2024
Q4 | $270K | Buy |
10,652
+2,532
| +31% | +$75K | 0.01% | 1497 |
|
|
2024
Q3 | $259K | Sell |
8,120
-16,560
| -67% | -$535K | 0.01% | 1380 |
|
|
2024
Q2 | $731K | Buy |
24,680
+24,660
| +123,300% | +$682K | 0.01% | 1013 |
|
|
2024
Q1 | $575 | Sell |
20
-2,864
| -99% | -$83.1K | ﹤0.01% | 5437 |
|
|
2023
Q4 | $82.3K | Sell |
2,884
-10,030
| -78% | -$235K | ﹤0.01% | 2782 |
|
|
2023
Q3 | $310K | Buy |
12,914
+10,844
| +524% | +$279K | 0.01% | 1162 |
|
|
2023
Q2 | $53.8K | Sell |
2,070
-5,232
| -72% | -$144K | ﹤0.01% | 2526 |
|
|
2023
Q1 | $198K | Sell |
7,302
-17,810
| -71% | -$503K | 0.01% | 1377 |
|
|
2022
Q4 | $725K | Buy |
25,112
+24,556
| +4,417% | +$691K | 0.03% | 511 |
|
|
2022
Q3 | $13K | Sell |
556
-27,598
| -98% | -$736K | ﹤0.01% | 4256 |
|
|
2022
Q2 | $681K | Buy |
28,154
+28,124
| +93,747% | +$716K | 0.02% | 939 |
|
|
2022
Q1 | $1K | Sell |
30
-21,476
| -100% | -$659K | ﹤0.01% | 5747 |
|
|
2021
Q4 | $872K | Sell |
21,506
-3,656
| -15% | -$157K | 0.02% | 765 |
|
|
2021
Q3 | $1.19M | Sell |
25,162
-13,588
| -35% | -$687K | 0.03% | 454 |
|
|
2021
Q2 | $1.91M | Sell |
38,750
-1,660
| -4% | -$72.4K | 0.05% | 327 |
|
|
2021
Q1 | $1.69M | Buy |
+40,410
| New | +$1.91M | 0.03% | 543 |
|
|
2020
Q4 | – | Sell |
-99,066
| Closed | -$3.47M | – | 5128 |
|
|
2020
Q3 | $3.47M | Buy |
99,066
+98,666
| +24,667% | +$3.5M | 0.04% | 155 |
|
|
2020
Q2 | $15K | Sell |
400
-1,360
| -77% | -$43.4K | ﹤0.01% | 3810 |
|
|
2020
Q1 | $41K | Sell |
1,760
-40,906
| -96% | -$1.14M | ﹤0.01% | 1379 |
|
|
2019
Q4 | $1.32M | Buy |
42,666
+33,136
| +348% | +$884K | 0.11% | 85 |
|
|
2019
Q3 | $202K | Sell |
9,530
-119,460
| -93% | -$2.83M | 0.01% | 999 |
|
|
2019
Q2 | $3.34M | Buy |
128,990
+109,584
| +565% | +$2.73M | 0.23% | 56 |
|
|
2019
Q1 | $539K | Sell |
19,406
-33,236
| -63% | -$895K | 0.03% | 556 |
|
|
2018
Q4 | $1.11M | Sell |
52,642
-1,544
| -3% | -$40.3K | 0.08% | 243 |
|
|
2018
Q3 | $1.89M | Buy |
54,186
+32,794
| +153% | +$1.07M | 0.14% | 112 |
|
|
2018
Q2 | $612K | Buy |
21,392
+21,070
| +6,543% | +$574K | 0.03% | 546 |
|
|
2018
Q1 | $9K | Sell |
322
-95,730
| -100% | -$2.87M | ﹤0.01% | 2490 |
|
|
2017
Q4 | $2.69M | Buy |
96,052
+95,922
| +73,786% | +$2.71M | 0.35% | 46 |
|
|
2017
Q3 | $4K | Sell |
130
-53,992
| -100% | -$1.54M | ﹤0.01% | 3372 |
|
|
2017
Q2 | $1.44M | Buy |
54,122
+38,574
| +248% | +$941K | 0.16% | 108 |
|
|
2017
Q1 | $375K | Sell |
15,548
-29,462
| -65% | -$685K | 0.04% | 178 |
|
|
2016
Q4 | $898K | Sell |
45,010
-57,334
| -56% | -$1.22M | 0.1% | 223 |
|
|
2016
Q3 | $2.48M | Sell |
102,344
-117,322
| -53% | -$2.79M | 0.25% | 44 |
|
|
2016
Q2 | $4.27M | Buy |
219,666
+34,062
| +18% | +$734K | 0.41% | 39 |
|
|
2016
Q1 | $3.79M | Buy |
185,604
+132,442
| +249% | +$2.93M | 0.56% | 29 |
|
|
2015
Q4 | $1.9M | Buy |
53,162
+50,488
| +1,888% | +$1.69M | 0.31% | 43 |
|
|
2015
Q3 | $78K | Sell |
2,674
-14,006
| -84% | -$597K | 0.01% | 715 |
|
|
2015
Q2 | $754K | Sell |
16,680
-31,576
| -65% | -$1.36M | 0.07% | 110 |
|
|
2015
Q1 | $1.91M | Sell |
48,256
-53,332
| -52% | -$1.98M | 0.24% | 59 |
|
|
2014
Q4 | $3.19M | Buy |
101,588
+27,524
| +37% | +$807K | 0.31% | 50 |
|
|
2014
Q3 | $1.92M | Sell |
74,064
-26,236
| -26% | -$636K | 0.22% | 88 |
|
|
2014
Q2 | $2.33M | Buy |
+100,300
| New | +$1.98M | 0.3% | 40 |
|
Other funds holding BIB
Tower Research Capital (TRC)'s BIB Position: Q3 2026 in Review
Tower Research Capital (TRC) opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2026: 712 shares worth $41.1K. The stake represents ﹤0.01% of the portfolio and ranks #3337 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BIB as recently as Q1 2026.
Tower Research Capital (TRC) first reported a position in BIB in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.27M in Q2 2016. 17 funds tracked by Wall St. Rank hold BIB as of Q3 2026.
- Tower Research Capital (TRC) held 712 shares of ProShares Ultra NASDAQ Biotechnology worth $41.1K as of Q3 2026.
- ProShares Ultra NASDAQ Biotechnology was a new Tower Research Capital (TRC) position in Q3 2026.
- ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3337 holding.
- Tower Research Capital (TRC) first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and has held it in 48 quarters since.
- Tower Research Capital (TRC)'s ProShares Ultra NASDAQ Biotechnology position peaked at $4.27M in Q2 2016.
- 17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.